161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM
Amrita Chauhan(Unknown), Geoffrey Shouse(City Of Hope National Medical Center), Yazeed Sawalha(Cleveland Clinic), R. Merryman(Dana-Farber Cancer Institute), Alex F. Herrera(City of Hope), Liangyi Chen(Peking University), Shakthi Bhaskar(Vanderbilt University Medical Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Allison M. Bock(Mayo Clinic), L. Falchi(Memorial Sloan Kettering Cancer Center), Amy Ayers(The University of Texas MD Anderson Cancer Center), Alexey V. Danilov(City of Hope), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(University of Utah), Sheela Godbole(The Ohio State University Wexner Medical Center), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew A. Lunning(University of Nebraska Medical Center), Andrew Jallouk(Vanderbilt University Medical Center), Christine Goth(City Of Hope National Medical Center)
Cited by 0
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574